Effectiveness and Safety of Recombinant Zoster Vaccine (RZV) in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA)
The vaccine effectiveness (VE) objectives are to estimate the VE of at least one RZV dose in preventing herpes zoster (HZ) in adults>=18 years of age with psoriasis (PsO) and psoriatic arthritis (PsA). The safety objectives are to assess the number of incident flare cases within 30 days following any RZV vaccination as compared to the risk in self-controlled comparison periods, in adults>=18 years of age with PsO and PsA.